Skip to content

A Study Comparing Two Monofocal, Aspheric, Hydrophobic Acrylic Intraocular Lenses: the Alcon CLAREON® and the Abbott Medical Optics PCB00

A Randomised, Controlled Study to Compare Visual Performance, Refractive Outcome, Forward Light Scatter, Patient Satisfaction and Objective Measurement of Glistenings Following Insertion of Two Monofocal, Aspheric, Hydrophobic Acrylic Intraocular Lenses: the Alcon CLAREON® and the Abbott Medical Optics PCB00 Lenses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03364972
Enrollment
145
Registered
2017-12-07
Start date
2018-02-06
Completion date
2019-08-01
Last updated
2019-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract Extraction, Cataract Surgery, Glistenings, Hydrophobic Acrylic, Intraocular Lens Implant, Light Scatter, Patient Related Outcome Measures, Patient Satisfaction, Phacoemulsification

Keywords

cataract, cataract extraction, interocular lens implant, glistenings, phacoemulsification, hydrophobic acrylic, light scatter, patient related outcome measures

Brief summary

This is a bilateral randomised controlled study to compare visual performance, refractive outcome, forward light scatter, patient satisfaction and objective measurement of glistenings following insertion of two monofocal, aspheric, hydrophobic acrylic intraocular lenses (IOLs). A new product is compared with an established one.

Interventions

DEVICECataract surgery

Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant

Sponsors

City, University of London
CollaboratorOTHER
King's College London
CollaboratorOTHER
Guy's and St Thomas' NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* bilateral cataracts * good visual potential * ability to understand informed consent and objectives of the trial * not-pregnant * not breast feeding * no previous eye surgery * corneal astigmatism less than 1 diopter in both eyes

Exclusion criteria

* age-related macula degeneration * glaucoma * previous retinal vascular disorders * previous retinal detachment or tear * any neuro-ophthalmological condition * any inherited retinal disorder or pathology * previous strabismus surgery or record of amblyopia * previous transient ischaemic attacks, cerebrovascular events or other vaso-occlusive disease * already enrolled in another study *

Design outcomes

Primary

MeasureTime frameDescription
Visual acuity13 monthsAs measured by conventional LogMAR visual acuity charts

Secondary

MeasureTime frameDescription
Incidence of intraocular lens glistenings13 monthsIncidence of presence of intraocular lens glistenings in each study arm
Severity of intraocular lens glistenings13 monthsNumber of vacuoles per square millimetre
Refraction (i.e. glasses prescription)13 monthsIn conventional sphere/cylinder dioptre scales: total range -40 to +40, in 0.25 steps. Higher values represent worse outcome. Values closer to 0 (zero) represent better outcome

Other

MeasureTime frameDescription
Forward light scatter13 monthsIntraocular (forward) light scatter is measured with a specifically devised computerised vision test. It is represented by straylight parameter, Log(s), on a logarithmic scale from 0 to 1.5. The lower the value (i.e. closer to 0), the better the outcome.
Contrast sensitivity13 monthsVisual acuity (LogMAR scale: total range -0.2 to 1.0 in 0.02 steps) measured at different contrasts with a computerized contrast sensitivity chart. Negative values, or values closer to 0, represent better outcome.
Patient satisfaction13 monthsValidated patient satisfaction questionnaire. We use specially designed and validated conversion tables to convert raw scores from questionnaires to Rasch calibrated measures.
Self-reported health13 monthsValidated self-reported health questionnaire. We use a vertical Visual Analogue Scale (VAS) to record patients' self-reported health on a scale from 0-100 (values closer or equal to 100 represent better outcome).

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026